undamentalytics Newsletter
Sign in

Adma Biologics, Inc. insider trading

Every open-market purchase and sale by Adma Biologics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $468,294 5 trades by 2 insiders 3 months later: median +17.8% (+13.1% vs S&P 500) Insider sales, 5 years $1.9M 6 trades by 2 insiders 3 months later: median −32.8% (−36.0% vs S&P 500)
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Adma Biologics, Inc.’s insiders pay?

From October 23, 2013 to May 28, 2026, 18 insiders reported 67 open-market purchases and 24 sales not made under a pre-set plan in Adma Biologics, Inc. Twelve months after each purchase was reported, the shares were −21.1% against the S&P 500 on average (median −35.2%), over 26 purchases with a full year of prices; 23% beat the index. After sales, the shares moved −0.5% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on October 24, 2013 into $4,681 by November 2, 2026, −5.7% a year. It held shares 32% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,715 (+5.8% a year), and held throughout $53,732 (+13.8%).

$0$20.0k$40.0k 2013201520172019202120232025 $53.7k$20.7k$4.7k
Copying Adma Biologics, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Adma Biologics, Inc.'s insiders from October 24, 2013, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 32% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Grossman Adam S President and CEO 21 −28.3% (14) 7% 5 +5.6% (3) November 22, 2024
Grossman Jerrold B Director 17 −19.9% (6) 33% 2 −52.0% (2) May 28, 2026
Lenz Brian EVP, CFO 8 −46.2% (1) 0% 1 — August 17, 2023
Guiheen Lawrence P. Director 4 +28.5% (1) 100% 3 −69.0% (3) June 11, 2025
Mond James EVP, CSO and CMO 5 −35.2% (1) 0% 0 — August 12, 2020
Elms Steve Director 1 — — 3 +115.5% (3) March 9, 2026
Edelman Joseph 10% owner 1 — — 2 — September 30, 2021
Kwon Young Director 2 — — 1 −16.3% (1) August 27, 2024
Perceptive Advisors LLC 10% owner 2 — — 1 — September 29, 2021
Richman Eric I Director 3 −36.6% (1) 0% 0 — June 11, 2018
Kestenberg-Messina Kaitlin M. COO and SVP, Compliance 0 — — 2 −16.9% (1) March 10, 2026
Biotest AG Director 1 — — 0 — November 13, 2017
Biotest Divestiture Trust 10% owner 0 — — 1 — June 7, 2019
Burrill Capital Fund IV, L.P. 10% owner 1 +28.5% (1) 100% 0 — October 23, 2013
Fong Bryant Director 0 — — 1 — August 23, 2023
Perceptive Life Sciences Master Fund Ltd 10% owner 0 — — 1 — August 19, 2021
Schiff Andrew N 10% owner 1 +28.5% (1) 100% 0 — October 23, 2013
Tade Brad L. CFO and Treasurer 0 — — 1 −26.4% (1) November 22, 2024

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Adma Biologics, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Adma Biologics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged −20.2% against the index. After 2 selling crowds, −2.4%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
May 29, 20262 buying+15.1%not yetnot yet
June 30, 20253 selling−27.0%−7.0%−74.8%
September 30, 20245 selling−15.4%+2.2%−45.4%
May 31, 20163 buying−35.7%−27.4%−69.7%
December 31, 20152 buying+4.9%−25.4%−48.6%
March 31, 20154 buying−5.7%−10.1%−19.1%
October 31, 20135 buying−0.8%−17.9%+24.6%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Adma Biologics, Inc. · Funds · Politicians